Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development, joins MINDCURE as Chief Medical Officer Post published:May 20, 2021 Post category:Press Release
MINDCURE Appoints Dr. John Brownstein, the Chief Innovation Officer at Boston Children’s Hospital, as Company Advisor Post published:May 19, 2021 Post category:Press Release
MINDCURE Shares Update on Strong Financial Position, Near Term Revenue Drivers and Timeline for iSTRYM’s Market Launch, Delivering Mental Wealth Post published:April 29, 2021 Post category:Press Release
MINDCURE Announces Partnership with SOMA Breath Inc. to License its Breathwork Program and Develop Custom Breathwork for Psychedelic-Assisted Psychotherapies within iSTRYM Post published:April 27, 2021 Post category:Press Release
MINDCURE Partners its iSTRYM Technology with LUCID to Discover and Create Proprietary Music Experiences for Use During Psychedelic-Assisted Therapy Sessions Post published:April 21, 2021 Post category:Press Release
MINDCURE Announces Partnership with Speak Ai to Enhance iSTRYM, the Company’s Psychedelic Digital Therapeutics Technology Platform Post published:April 13, 2021 Post category:Press Release
MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors Post published:April 8, 2021 Post category:Press Release
MINDCURE Files Provisional Patent Application For iSTRYM, its Proprietary AI Digital Therapeutics (DTx) SaaS Platform, Designed To Enhance Effectiveness Of Psychedelic-Assisted Therapies For Practitioners And Patients Post published:March 31, 2021 Post category:Press Release
Ty Tashiro joins MINDCURE as the Senior Translational and Psychometric Architect for iSTRYM’s AI-Driven Psychedelic Digital Therapeutic Technology Post published:March 19, 2021 Post category:Press Release
MINDCURE Names Tarik Lebbadi as Chief Operating Officer Post published:March 15, 2021 Post category:Press Release